BLPH

Bellerophon Therapeutics Inc.

Price

return (12m)

0.00%

p/e

0.59

p/bv

0.13

DIVIDEND YIELD

0.00%

BLPH price

Bellerophon Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BLPH

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Fundamentals BLPH

Valuation

P/E

0.59

Sector -2.34

Industry 11.10

P/BV

0.13

Sector 2.17

Industry 3.33

P/Revenue (PSR)

Sector 2.00

Industry 1.71

EV/EBITDA

Sector -23.69

Industry -398.52

EV/EBIT

Sector -36.60

Industry -80.73

P/EBITDA

-0.02

Sector -0.10

Industry 8.30

P/EBIT

-0.02

Sector -2.08

Industry 5.69

P/Total Assets

0.10

Sector 1.18

Industry 1.57

P/Net Current Assets

Sector -10.91

Industry -3.38

P/Working Capital

Sector 0.09

Industry 10.51

EPS

0.07

Sector -0.93

Industry 1.10

BVPS

0.30

Sector 3.87

Industry 14.82

Efficiency

Gross Margin

0.00%

Sector 44.28%

Industry 29.23%

EBITDA Margin

Sector -291.45%

Industry 4.29%

EBIT Margin

Sector -195.44%

Industry 1.44%

Operating Margin

0.00%

Sector -25.72%

Industry 2.16%

Net Profit Margins

0.00%

Sector -30.19%

Industry 2.77%

Asset Turnover

0.00

Sector 0.12

Industry 0.27

Profitability

ROE

22.35%

Sector -34.71%

Industry 6.97%

ROA

16.71%

Sector -28.76%

Industry 2.97%

ROIC

Sector -441.27%

Industry -5.31%

Dividends

Dividend yield

0.00%

Sector -

Industry 0.01%

Payout

0.00%

Sector -

Industry 0.54%

Debt

Current Ratio

Sector 1.87

Industry 1.51

Net Debt / EBITDA

Sector -2.18

Industry -1.68

Net Debt / EBIT

Sector -0.74

Industry -7.00

Net Debt / Equity

Sector -0.34

Industry 0.05

Gross Debt / Equity

Sector -0.64

Industry 0.35

Equity/Assets

0.75

Sector 0.43

Industry 0.46

Liabilities/Assets

0.75

Sector 0.46

Industry 0.52

Growth

5Y Revenue CAGR

0.00%

Sector -

Industry -

5Y Earnings CAGR

0.00%

Sector -

Industry -

FAIR VALUE OF Bellerophon Therapeutics ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffett’s mentor.

Current price

$0.00

Fair Value

$0.69

Upside Return potential.

See Graham's ranking

Because it considers equity value in its calculation, this formula may not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals BLPH

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BLPH Bellerophon Therapeutics Inc.	$0.00	-	0.00%	0.59	0.13	22.35%	0.00%
EW Edwards Lifesciences Corp.	$78.21	12.69%	0.00%	45.55	4.82	10.58%	17.34%
BSX Boston Scientific Corp.	$63.80	-31.89%	0.00%	18.45	2.54	13.78%	17.29%
ABT Abbott Laboratories	$101.06	-18.35%	0.00%	25.64	3.09	12.06%	13.91%
ABMD Abiomed Inc.	$0.00	-	0.00%	64.27	11.14	17.32%	24.84%
ALGN Align Technology Inc.	$184.69	12.52%	0.00%	27.86	2.89	10.36%	10.50%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BLPH Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Bellerophon Therapeutics

Bellerophon Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

States of America

13 years

Founded: 2013

2015

Time since IPO - 11 years

21

Employees

Bellerophon Therapeutics Inc. (States of America) is listed on the Nasdaq and has a market capitalization of $489.31 Thousand, with shareholders equity totaling $3.72 million.

The company employs approximately 21 people and operates in the Saúde sector, within the Materiais e Equipamentos Médicos industry.

Over the past 12 months, Bellerophon Therapeutics Inc. reported $- in revenue, generating net income of $831.98 Thousand.

Key financial metrics include a P/E ratio of 0.59, a price-to-book (P/B) ratio of 0.13, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BLPH.

Market cap

$489.31 Thousand

Net worth

$3.72 million

$3,723,000.00

Assets

$4.98 million

$4,979,000.00

Total Shares Outstanding

12.23 million

12,232,000

Average Daily Trading Volume

Sector

Saúde

Industry

Materiais e Equipamentos Médicos

BLPH

BLPH revenue and profits

Financial Results BLPH

DRAG THE FRAME TO SEE MORE DATA

BLPH cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

CVS - CVS Health

$77.63 34,88% (12M)

P/E

46.88

2.46%

ROE

3.78%

P/BV

1.77

CI - Cigna

$272.65 --5,23% (12M)

P/E

11.58

2.16%

ROE

15.39%

P/BV

1.78

CNC - Centene

$37.26 38,72% (12M)

P/E

-4.98

0.00%

ROE

-29.93%

P/BV

1.49

HUM - Humana

$196.30 --14,19% (12M)

P/E

42.07

0.89%

ROE

6.06%

P/BV

2.55

SNY - Sanofi

$47.64 --3,72% (12M)

P/E

7.21

4.00%

ROE

17.79%

P/BV

1.28

LLY - Eli Lilly

$923.03 21,62% (12M)

P/E

41.74

0.55%

ROE

81.02%

P/BV

33.82

HCA - HCA Healthcare

$498.78 47,18% (12M)

P/E

12.41

0.80%

ROE

-228.14%

P/BV

-28.31

NVS - Novartis

$153.41 34,63% (12M)

P/E

21.74

2.01%

ROE

34.77%

P/BV

7.56